2025-07-23 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the provided data, formatted as a concise English report with key numbers highlighted, followed by analysis:

## Merck & Co Inc (MRK) Stock Analysis

**Company Overview:** Merck & Co Inc is a global pharmaceutical company focused on innovative medicines, vaccines, and animal health products.

**1. Performance vs. S&P 500 (VOO):**

*   **MRK Cumulative Return:** -4.40%
*   **VOO Cumulative Return:** 97.07%
*   **Absolute Divergence (Current):** -102.3
*   **Relative Divergence:** 0.0

**Analysis:** MRK has significantly underperformed the S&P 500 (VOO) over the period examined. The cumulative return is drastically lower, resulting in a large negative divergence. The relative divergence indicates MRK is at the very bottom of its historical performance range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha     | Beta     | Cap(B)  |
|------------|----------|----------|-----------|----------|---------|
| 2015-2017  | 5.0%     | 58.2%    | -24.0%    | -0.0     | 134.8   |
| 2016-2018  | 43.0%    | 66.4%    | 25.0%     | -0.1     | 183.1   |
| 2017-2019  | 40.0%    | 66.4%    | 11.0%     | 0.3      | 217.9   |
| 2018-2020  | 20.0%    | 66.4%    | 0.0%      | 0.3      | 196.0   |
| 2019-2021  | -1.0%    | 65.6%    | -50.0%    | 0.3      | 192.4   |
| 2020-2022  | 13.0%    | 69.5%    | 11.0%     | 0.3      | 278.6   |
| 2021-2023  | 31.0%    | 69.5%    | 13.0%     | 0.3      | 273.8   |
| 2022-2024  | -7.0%    | 69.5%    | -33.0%    | 0.2      | 249.8   |
| 2023-2025  | -56.0%   | 68.9%    | -105.0%   | 0.5      | 204.9   |

**Analysis:**

*   **CAGR:** Fluctuates significantly, with a recent sharp decline.
*   **MDD:** Relatively high, indicating substantial drawdowns.
*   **Alpha:** Mostly negative in recent periods, suggesting underperformance relative to its risk.
*   **Beta:** Generally low, indicating lower sensitivity to market movements.
*   **Cap:** Market capitalization has varied over the years.

**2. Recent Stock Price Movement:**

*   **Current Price:** 81.61
*   **Previous Close:** 79.31
*   **Change:** 2.9
*   **5-day Moving Average:** 80.97
*   **20-day Moving Average:** 81.40
*   **60-day Moving Average:** 79.86

**Analysis:** The stock price is currently above its 5-day and 20-day moving averages, suggesting a short-term upward trend.  The recent large price increase from the previous close (change of 2.9) could indicate some recent positive news or market reaction.

**3. Technical Indicators & Expected Return:**

*   **Market Risk Indicator (MRI):** 0.3359 (Low Risk)
*   **RSI:** 49.33 (Neutral)
*   **PPO:** -0.37 (Negative)
*   **Hybrid Signal:** cash_69%_Sell 0.6% of holdings
*   **Delta_Previous_Relative_Divergence:** -3.3 (Short-term decrease)
*   **Expected Return (%):** -1133.5%

**Analysis:**

*   MRI suggests low market risk.
*   RSI is neutral, not indicating overbought or oversold conditions.
*   PPO is negative, suggesting a potential downtrend.
*   The hybrid signal indicates a cautious stance, recommending selling a small portion of holdings and holding a significant cash position.
*   The negative change in relative divergence indicates short-term downward pressure.
*   The extremely negative expected return is a *major* red flag, suggesting significant potential underperformance compared to the S&P 500 over the long term.

**4. Recent News & Significant Events:**

*   **[2025-07-19]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-23]:** Analysts discussing recent performance and outlook.
*   **[2025-07-20]:** Stock showing notable volatility.
*   **[2025-07-22]:** Market experts highlighting both risks and opportunities.

**Analysis:** Recent news indicates volatility and active discussion surrounding the company's performance. Investors should carefully monitor further developments.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue        |
|------------|------|----------------|
| 2025-05-02 | 2.01 | $15.53 B      |
| 2024-11-06 | 1.25 | $16.66 B      |
| 2024-08-05 | 2.15 | $16.11 B      |
| 2024-05-03 | 1.88 | $15.78 B      |
| 2025-05-02 | 1.88 | $15.78 B      |

**Analysis:**

*   EPS and Revenue show some fluctuation but appear relatively stable over the recent quarters.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue     | Profit Margin |
|------------|-------------|---------------|
| 2025-03-31 | $15.53B     | 77.98%        |
| 2024-12-31 | $15.62B     | 75.50%        |
| 2024-09-30 | $16.66B     | 75.51%        |
| 2024-06-30 | $16.11B     | 76.76%        |
| 2024-03-31 | $15.78B     | 77.56%        |

**Capital and Profitability:**

| Quarter    | Equity      | ROE     |
|------------|-------------|---------|
| 2025-03-31 | $48.34B     | 10.51%  |
| 2024-12-31 | $46.31B     | 8.08%   |
| 2024-09-30 | $44.50B     | 7.09%   |
| 2024-06-30 | $43.58B     | 12.52%  |
| 2024-03-31 | $40.36B     | 11.80%  |

**Analysis:**

*   **Revenue:** Relatively stable revenue over the past five quarters.
*   **Profit Margin:** High and consistent profit margins.
*   **Equity:** Increasing equity.
*   **ROE:** Fluctuating ROE.

**7. Overall Summary:**

Merck & Co Inc (MRK) is currently showing mixed signals. While the company has strong financial health with stable revenue, high profit margins, and increasing equity, its stock performance has been significantly lagging the S&P 500. Recent news indicates volatility and analyst attention. The extremely negative expected return is a major concern. The hybrid signal suggests a cautious approach.

**Recommendation:** Given the significant underperformance, negative expected return, and cautious hybrid signal, investors should exercise caution with MRK. Further research into the specific reasons for the underperformance and the company's future outlook is strongly recommended before making any investment decisions. Monitor upcoming news and analyst reports closely.
